Holdings (36)
Name | Sector | Instrument | Assets |
---|---|---|---|
Sun Pharmaceutical Industries Ltd. | Healthcare | Equity | 12.23% |
Divi's Laboratories Ltd. | Healthcare | Equity | 8.5% |
Lupin Ltd. | Healthcare | Equity | 6.07% |
Cipla Ltd. | Healthcare | Equity | 5.62% |
Apollo Hospitals Enterprise Ltd. | Healthcare | Equity | 5.48% |
Dr. Reddy's Laboratories Ltd. | Healthcare | Equity | 5.18% |
Medplus Health Services Ltd. | Healthcare | Equity | 3.83% |
Glaxosmithkline Pharmaceuticals Ltd. | Healthcare | Equity | 3.63% |
Narayana Hrudayalaya Ltd. | Healthcare | Equity | 3.55% |
Vijaya Diagnostic Centre Ltd. | Healthcare | Equity | 3.32% |
Returns and rankings
1Y | 3Y | 5Y | All | |
---|---|---|---|---|
Fund Returns | 6.12% | 24.39% | 20.67% | 17.73% |
Category Average | 6.89% | 22.67% | 19.03% | NA% |
Rank Within Category | 10.00% | 4.00% | 5.00% | NA% |
Expense ratio, exit load and tax
Expense ratio: 0.89%
Inclusive of GST
Exit load
Exit load of 1% if redeemed within 1 month.
Stamp duty
0.005% (from July 1st, 2020)
Tax implication
If you redeem within one year, returns are taxed at 20%. If you redeem after one year, returns exceeding Rs 1.25 lakh in a financial year are taxed at 12.5%.
Fund management
Education
Mr. Bhan is an MBA (Finance) and CFA.
Experience
Prior to joining Nippon India Mutual Fund, he has worked with Emkay Share & Stock Broker Pvt. Ltd, Shah & Sequeira Invst. Pvt. Ltd, ICFAI- Securities Research Center Analyst - Equity Research.
Managed Schemes
Nippon India Large Cap Fund Direct Growth
Nippon India Multi Cap Fund Direct Growth
Nippon India Pharma Fund Direct Growth
Reliance Close Ended Equity Fund Series A Direct Growth
Reliance Close Ended Equity Fund Series B Direct Growth
Reliance Close Ended Equity Fund II Series A Direct Growth
Nippon India India Opportunities Fund Series A Direct Growth